Loading data for PROK — first visit, this takes a few seconds.
ProKidney Corp.
2.01 +0.09 (4.69%)
- Рыночная капитализация
- $722.5M
- Объём торгов
- 1.23M
- Следующая дата отчётности
- Nov 9, 2026
ProKidney Corp. (PROK): цена акции, анализ и данные
Внутренняя стоимость
Прогноз аналитиков
Прогнозы по акции →Последние результаты
| Отчитано | К прогнозу | Изменение г/г | |
|---|---|---|---|
| Выручка | $150.0K | n/a | -32.13% |
| EPS | -$0,15 | -$0,01 | -15.38% |
Метрики
- Бид
- 1.45
- Выручка (TTM)
- 818K
- Чистая прибыль (TTM)
- -84.2M
- 1.75
- -0.55
- n/a
- -3.09
- P/B (TTM)
- -0.42
- P/S (TTM)
- 883.28
- Дата отчёта
- Nov 9, 2026
- Аск
- 2.45
- Объём торгов
- 1,225,328
- Ср. объём (20д)
- 1,205,190
- Открытие
- 1.90
- Пред. закрытие
- 1.92
- Диапазон дня
- 1.89 - 2.09
- Диапазон за 52 недели
- 1.30 - 3.48
- Аналитики
- n/a
- Целевая цена
- n/a
- Дивиденды
- n/a
- Дата отсечки
- n/a
О компании ProKidney Corp.
Профиль →ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Отрасль Biotechnology
Сектор Healthcare
Дата IPO Jun 30, 2021
Сотрудники 231
Биржа NasdaqCM
Тикер PROK